Polymorphism of IL-1α, IL-1β and IL-10 in patients with advanced ovarian cancer: Results of a prospective study with 147 patients

详细信息	查看全文 | 推荐本文 |

• 作者：Elena Ioana Braicu ; Alex ; er Mustea ; Mohammad R. Toliat ; Cristina Pirvulescu ; Dominique Kö ; nsgen ; Pengming Sun ; Peter Nü ; rnberg ; Werner Lichtenegger ; Jalid Sehouli
• 关键词：Ovarian cancer ; Cytokines ; Polymorphism ; IL-1α ; ; IL-1β ; ; IL-10
• 刊名：Gynecologic Oncology
• 出版年：2007
• 期刊代码：295_00908258
• 类别：med
• 出版时间：March 2007
• 卷：104
• 期：3
• 页码：680-685
• 文件大小：139 K

摘要

>Objective.

Interleukin 1 (IL-1) and IL-10 are critically involved in tumorigenesis. We investigated polymorphisms of IL-1 and IL-10 genes in patients with ovarian cancer (OC).

Methods.

In a prospective, case–control study 147 patients with OC and 129 patients without history of any malignancy (CG) were genotyped for IL-1 gene (IL-1α − 889 T/C and IL-1β − 511 C/T) and IL-10 gene (IL-10 − 1082 G/A, − 819 C/T and − 592 C/A) using pyrosequencing.

Results.

IL-10 polymorphisms in − 819 and − 592 positions correlated with the postoperative residual tumor mass (p = 0.036 and p = 0.035, respectively). The chance of achieving optimal tumor debulking was 1.49 times greater for patients with the C/C genotype at − 819 and − 512 positions than for patients with other genotypes. There were no significant associations between allelic frequencies for IL-1α and IL-1β in OC. IL-10 − 819 CC and − 592 CC genotypes were associated in univariate analysis with a better disease-free and overall survival.

Conclusions.

IL-10 promoter polymorphism may be related with the ability to achieve optimal tumor debulking. Polymorphism in IL-10 gene seems to influence the overall and disease-free survival rate. Subsequent multi-institutional studies with high number of patients are warranted to confirm these results.